$STME
Stimcell Energetics Inc.

2024 Q3 Form 10-K Financial Statement

#000139390524000308 Filed on August 29, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2024
Revenue $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue $0.00 $0.00
YoY Change -100.0% -100.0%
Gross Profit $0.00 $0.00
YoY Change -100.0% -100.0%
Gross Profit Margin
Selling, General & Admin $119.0K $290.9K
YoY Change 86.32% -18.95%
% of Gross Profit
Research & Development -$2.060K -$22.54K
YoY Change -590.48% -125.26%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $59.64K $117.0K $268.4K
YoY Change 16.81% 81.9% -40.12%
Operating Profit -$117.0K -$268.4K
YoY Change 80.55% -40.05%
Interest Expense $8.852K -$8.000K $61.65K
YoY Change -65.82% -45.24% 30.11%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$125.0K -$142.5K
YoY Change 57.42% -71.22%
Income Tax
% Of Pretax Income
Net Earnings -$66.92K -$125.0K -$142.5K
YoY Change -13.04% 57.42% -71.22%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 297.2M shares 297.2M shares 161.0M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q3 2024 Q2 2024
SHORT-TERM ASSETS
Cash & Short-Term Investments $43.42K $43.42K
YoY Change -55.83% -55.83%
Cash & Equivalents $20.55K $43.42K
Short-Term Investments
Other Short-Term Assets $1.845K $2.707K $2.710K
YoY Change -56.61% -45.59% -45.58%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $46.12K $46.12K
YoY Change -55.34% -55.34%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $2.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $46.12K $46.12K
Total Long-Term Assets $2.00 $0.00
Total Assets $22.40K $46.12K $46.12K
YoY Change -64.06% -55.34% -55.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $311.2K $288.9K $288.9K
YoY Change -15.92% -29.24% -29.24%
Accrued Expenses $6.705K $28.06K $28.06K
YoY Change -84.22% -23.25% -23.25%
Deferred Revenue
YoY Change
Short-Term Debt $324.5K $324.5K
YoY Change -68.82% -68.82%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $872.6K $872.6K
YoY Change -64.94% -64.94%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $872.6K $872.6K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $931.1K $872.6K $872.6K
YoY Change -63.25% -64.94% -64.94%
SHAREHOLDERS EQUITY
Retained Earnings -$10.36M -$10.30M
YoY Change 1.29% 1.4%
Common Stock $297.2K $297.2K
YoY Change 372.38% 372.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$826.5K -$826.5K
YoY Change
Total Liabilities & Shareholders Equity $22.40K $46.12K $46.12K
YoY Change -64.06% -55.34% -55.34%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2024
OPERATING ACTIVITIES
Net Income -$66.92K -$125.0K -$142.5K
YoY Change -13.04% 57.42% -71.22%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$22.92K -$32.27K -$145.9K
YoY Change -43.21% 25.96% -46.4%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -3.970K $91.03K
YoY Change -103.41% -73.72%
NET CHANGE
Cash From Operating Activities -$22.92K -32.27K -$145.9K
Cash From Investing Activities
Cash From Financing Activities -3.970K $91.03K
Net Change In Cash -$22.86K -36.24K -$54.88K
YoY Change -43.16% -139.93% -174.25%
FREE CASH FLOW
Cash From Operating Activities -$22.92K -$32.27K -$145.9K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024 dei Document Type
DocumentType
10-K
CY2024 dei Document Annual Report
DocumentAnnualReport
true
CY2024 dei Document Period End Date
DocumentPeriodEndDate
2024-05-31
CY2024 dei Document Transition Report
DocumentTransitionReport
false
CY2024 dei Entity File Number
EntityFileNumber
000-54500
CY2024 dei Entity Registrant Name
EntityRegistrantName
Cell MedX Corp.
CY2024 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2024 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
38-3939625
CY2024 dei Entity Address Address Line1
EntityAddressAddressLine1
1130 Pender Street, West
CY2024 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 820
CY2024 dei Entity Address City Or Town
EntityAddressCityOrTown
Vancouver
CY2024 dei Entity Address State Or Province
EntityAddressStateOrProvince
BC
CY2024 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
V6E 4A4
CY2024 dei City Area Code
CityAreaCode
844
CY2024 dei Local Phone Number
LocalPhoneNumber
238-2692
CY2024 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2024 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2024 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2024 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
No
CY2024 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024 dei Entity Small Business
EntitySmallBusiness
true
CY2024 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2024 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2024 dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Public Float
EntityPublicFloat
490813 usd
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
297236373 shares
CY2024 dei Auditor Name
AuditorName
DALE MATHESON CARR-HILTON LABONTE LLP
CY2024 dei Auditor Location
AuditorLocation
Vancouver, Canada
CY2024 dei Auditor Firm
AuditorFirmId
1173
CY2024Q2 us-gaap Cash
Cash
43415 usd
CY2023Q2 us-gaap Cash
Cash
98295 usd
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
2707 usd
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
4975 usd
CY2024Q2 us-gaap Assets
Assets
46122 usd
CY2023Q2 us-gaap Assets
Assets
103270 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
288891 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
408264 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28058 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
36560 usd
CY2024Q2 fil Due To Related Party Current
DueToRelatedPartyCurrent
231138 usd
CY2023Q2 fil Due To Related Party Current
DueToRelatedPartyCurrent
1003187 usd
CY2024Q2 fil Notes And Advances Due To Related Parties
NotesAndAdvancesDueToRelatedParties
324490 usd
CY2023Q2 fil Notes And Advances Due To Related Parties
NotesAndAdvancesDueToRelatedParties
875130 usd
CY2024Q2 us-gaap Notes Payable
NotesPayable
0 usd
CY2023Q2 us-gaap Notes Payable
NotesPayable
165609 usd
CY2024Q2 us-gaap Liabilities
Liabilities
872577 usd
CY2023Q2 us-gaap Liabilities
Liabilities
2488750 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
7500000000 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
7500000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
297236373 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62923063 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
297236 usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
62923 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
8736081 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
7272701 usd
CY2024Q2 fil Reserves
Reserves
366493 usd
CY2023Q2 fil Reserves
Reserves
366493 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-10295263 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-10152777 usd
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
68998 usd
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
65180 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-826455 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2385480 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
46122 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
103270 usd
CY2024 us-gaap Revenues
Revenues
0 usd
CY2023 us-gaap Revenues
Revenues
2762 usd
CY2024 fil Costs Of Goods Sold
CostsOfGoodsSold
0 usd
CY2023 fil Costs Of Goods Sold
CostsOfGoodsSold
2279 usd
CY2024 us-gaap Gross Profit
GrossProfit
0 usd
CY2023 us-gaap Gross Profit
GrossProfit
483 usd
CY2024 us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
129956 usd
CY2023 us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
83387 usd
CY2024 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
160935 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
275534 usd
CY2024 fil Research And Development Expense Increase And Decrease
ResearchAndDevelopmentExpenseIncreaseAndDecrease
-22539 usd
CY2023 fil Research And Development Expense Increase And Decrease
ResearchAndDevelopmentExpenseIncreaseAndDecrease
89220 usd
CY2024 us-gaap Operating Expenses
OperatingExpenses
268352 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
448141 usd
CY2024 us-gaap Extinguishment Of Debt Gain Loss Net Of Tax
ExtinguishmentOfDebtGainLossNetOfTax
187517 usd
CY2023 us-gaap Extinguishment Of Debt Gain Loss Net Of Tax
ExtinguishmentOfDebtGainLossNetOfTax
0 usd
CY2024 us-gaap Interest Expense
InterestExpense
61651 usd
CY2023 us-gaap Interest Expense
InterestExpense
47384 usd
CY2024 us-gaap Profit Loss
ProfitLoss
-142486 usd
CY2023 us-gaap Profit Loss
ProfitLoss
-495042 usd
CY2024 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
3818 usd
CY2023 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
118593 usd
CY2024 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-138668 usd
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-376449 usd
CY2024 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2024 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
161008445 shares
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62923063 shares
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2009031 usd
CY2023 us-gaap Profit Loss
ProfitLoss
-495042 usd
CY2023 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
118593 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2385480 usd
CY2024 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
1622693 usd
CY2024 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
75000 usd
CY2024 us-gaap Profit Loss
ProfitLoss
-142486 usd
CY2024 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
3818 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-826455 usd
CY2024 us-gaap Profit Loss
ProfitLoss
-142486 usd
CY2023 us-gaap Profit Loss
ProfitLoss
-495042 usd
CY2024 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
49927 usd
CY2023 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
47384 usd
CY2024 us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
11724 usd
CY2023 us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
0 usd
CY2024 us-gaap Extinguishment Of Debt Gain Loss Net Of Tax
ExtinguishmentOfDebtGainLossNetOfTax
187517 usd
CY2023 us-gaap Extinguishment Of Debt Gain Loss Net Of Tax
ExtinguishmentOfDebtGainLossNetOfTax
0 usd
CY2024 us-gaap Unrealized Gain Loss On Foreign Currency Derivatives Net Before Tax
UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
-6380 usd
CY2023 us-gaap Unrealized Gain Loss On Foreign Currency Derivatives Net Before Tax
UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
-71141 usd
CY2024 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-2278 usd
CY2023 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-11408 usd
CY2024 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
46750 usd
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-14064 usd
CY2024 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-8500 usd
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
7770 usd
CY2024 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
75546 usd
CY2023 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
99194 usd
CY2024 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-145898 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-272209 usd
CY2024 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
16033 usd
CY2023 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
296364 usd
CY2024 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 usd
CY2023 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
50000 usd
CY2024 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
75000 usd
CY2023 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0 usd
CY2024 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
91033 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
346364 usd
CY2024 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
-15 usd
CY2023 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
-240 usd
CY2024 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-54880 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
73915 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
98295 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24380 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43415 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
98295 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-10295263 usd
CY2024 us-gaap Use Of Estimates
UseOfEstimates
<p style="font:10pt Times New Roman;margin:0;text-align:justify"><b>Accounting estimates</b></p> <p style="font:10pt Times New Roman;margin:0;text-align:justify">The preparation of these consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company regularly evaluates estimates and assumptions related to the fair value of stock-based compensation, fair value of financial instruments and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</p>
CY2024Q2 fil Due To Related Party Current
DueToRelatedPartyCurrent
231138 usd
CY2023Q2 fil Due To Related Party Current
DueToRelatedPartyCurrent
1003187 usd
CY2024 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
167456 usd
CY2023 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
159713 usd
CY2024Q2 us-gaap Loans Payable
LoansPayable
287466 usd
CY2024Q2 us-gaap Interest Payable Current
InterestPayableCurrent
37024 usd
CY2024Q2 fil Notes And Advances Due To Related Parties
NotesAndAdvancesDueToRelatedParties
324490 usd
CY2023Q2 us-gaap Loans Payable
LoansPayable
809115 usd
CY2023Q2 us-gaap Interest Payable Current
InterestPayableCurrent
66015 usd
CY2023Q2 fil Notes And Advances Due To Related Parties
NotesAndAdvancesDueToRelatedParties
875130 usd
CY2024Q2 fil Notes Payable Related Parties Other
NotesPayableRelatedPartiesOther
11000 usd
CY2023Q2 fil Notes Payable Related Parties Other
NotesPayableRelatedPartiesOther
39715 usd
CY2024Q2 us-gaap Other Loans Payable
OtherLoansPayable
0 usd
CY2024Q2 us-gaap Interest And Dividends Payable Current
InterestAndDividendsPayableCurrent
0 usd
CY2024Q2 us-gaap Notes Payable
NotesPayable
0 usd
CY2023Q2 us-gaap Other Loans Payable
OtherLoansPayable
143936 usd
CY2023Q2 us-gaap Interest And Dividends Payable Current
InterestAndDividendsPayableCurrent
21673 usd
CY2023Q2 us-gaap Notes Payable
NotesPayable
165609 usd
CY2024Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
1622693 usd
CY2024Q2 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
231813310 shares
CY2024Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
1622693 usd
CY2024Q2 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
231813310 shares
CY2024 us-gaap Extinguishment Of Debt Gain Loss Net Of Tax
ExtinguishmentOfDebtGainLossNetOfTax
187517 usd
CY2024 us-gaap Gross Profit
GrossProfit
0 usd
CY2023 us-gaap Gross Profit
GrossProfit
483 usd
CY2024Q2 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
231813310 shares
CY2024Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
1622693 usd
CY2024Q2 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
0.007
CY2024 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2500000 shares
CY2024Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
0.03
CY2024 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
75000 usd
CY2024 us-gaap Temporary Equity Description
TemporaryEquityDescription
Each Unit sold under the Offering consisted of one common share of the Company and one share purchase warrant (the “Warrant”) expiring on March 12, 2026. Each Warrant can be exercised into one share of the Company’s common stock at $0.04 per share expiring on September 12, 2024, and at $0.05 per share during the remaining life of the Warrant
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
2500000 shares
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.35
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0 shares
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
2500000 shares
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
0 shares
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
0 shares
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
2988000 shares
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2500000 shares
CY2024 us-gaap Profit Loss
ProfitLoss
-142486 usd
CY2023 us-gaap Profit Loss
ProfitLoss
-495042 usd
CY2024 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2024 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-30000 usd
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-104000 usd
CY2024 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
10000 usd
CY2023 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
23000 usd
CY2024 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
0 usd
CY2023 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-10000 usd
CY2024 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
16000 usd
CY2023 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
0 usd
CY2024 us-gaap Income Tax Credits And Adjustments
IncomeTaxCreditsAndAdjustments
-11000 usd
CY2023 us-gaap Income Tax Credits And Adjustments
IncomeTaxCreditsAndAdjustments
11000 usd
CY2024 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
15000 usd
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
80000 usd
CY2024Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
1411000 usd
CY2023Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
1383000 usd
CY2024Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
463000 usd
CY2023Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
474000 usd
CY2024Q2 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
3000 usd
CY2023Q2 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
5000 usd
CY2024Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1877000 usd
CY2023Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1862000 usd
CY2024Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2023Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2024Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
6720000 usd
CY2024Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
2054000 usd
CY2024Q2 fil Net Operating Losses Which May Be Carried Forward Foreign
NetOperatingLossesWhichMayBeCarriedForwardForeign
1716000 usd
CY2023Q2 fil Net Operating Losses Which May Be Carried Forward Foreign
NetOperatingLossesWhichMayBeCarriedForwardForeign
1756000 usd

Files In Submission

Name View Source Status
0001393905-24-000308-index-headers.html Edgar Link pending
0001393905-24-000308-index.html Edgar Link pending
0001393905-24-000308.txt Edgar Link pending
0001393905-24-000308-xbrl.zip Edgar Link pending
cmxc-20240531.htm Edgar Link pending
cmxc-20240531.xsd Edgar Link pending
cmxc10k_1.jpg Edgar Link pending
cmxc10k_2.jpg Edgar Link pending
cmxc_ex311.htm Edgar Link pending
cmxc_ex312.htm Edgar Link pending
cmxc_ex321.htm Edgar Link pending
cmxc_ex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
cmxc-20240531_htm.xml Edgar Link completed
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cmxc-20240531_cal.xml Edgar Link unprocessable
cmxc-20240531_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cmxc-20240531_pre.xml Edgar Link unprocessable
cmxc-20240531_lab.xml Edgar Link unprocessable